Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/26350
Title: Phase II study of concurrent chemoradiotherapy for inoperable (Bulky) stage III (A/B) Non-Small Cell Lung Cancer (NSCLC) : A preliminary report
Authors: Vorachai Ratanatharathorn
Puangthong Kraipiboon
Savitree Maoleekoonpairoj
Arkom Cheirsilpa
Vichien Srimuninnimit
Prasert Lertsanguansinchai
Vicharn Lorvidhaya
Ekaphop Sirachainan
Pramook Phromratanapongse
Saipin Tangkaratt
Pitayapoon Pattaranutaporn
Mahidol University
Chiang Mai University
Pramongkutklao Hospital
National Cancer Institute Thailand
Chulalongkorn University
Keywords: Medicine
Issue Date: 1-Jan-2000
Citation: Journal of the Medical Association of Thailand. Vol.83, No.1 (2000), 85-92
Abstract: We designed a phase II study to determine the feasibility and toxicity of concomitant radiotherapy and Paclitaxel/Carboplatin followed by adjuvant chemotherapy of the same regimen in patients with newly diagnosed inoperable stage III A/B non-small cell lung cancer. Patients were irradiated with a total dose of 66 Gy. Weekly courses of Paclitaxel 45 mg/m2 and Carboplatin AUC 2 were administered intravenously during the irradiation period. After completion of concurrent chemoradiotherapy, adjuvant chemotherapy with Paclitaxel 175 mg/m2 and Carboplatin AUC 6 intravenously every 3 weeks for 4 cycles were given. Since March 1998, 15 patients have been enrolled. All patients were assessable for efficacy and toxicity after concurrent chemoradiotherapy. Eleven patients were assessable for efficacy and toxicity after adjuvant chemotherapy. After concomitant chemoradiotherapy, complete response (CR) was documented in 2 of 15 (13%). Partial response (PR) was documented in 9 of 15 (60%). After completion of adjuvant chemotherapy in 11 patients, the overall response rate was 91 per cent. (18% CR, 73% PR). There were 8 per cent gr. 3-4 neutropenia which occurred during adjuvant chemotherapy. Concomitant Paclitaxel/Carboplatin and radiotherapy are promising modalities in the treatment of inoperable stage III A/B non-small cell lung cancer.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0034012127&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/26350
ISSN: 01252208
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.